Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Medican Enterprises, Inc. (MDCN)
Los Angeles, CA, US
Medican Enterprises, Inc. is a bio-pharmaceutical company, which engages in the production, cultivation, and wholesale distribution of cannabis related products. The company was founded on October 27, 1988 and is headquartered in Los Angeles, CA.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +9,900.00% | +0.00% | +9,900.00% | +0.00% | +9,900.00% | +0.00% | +199,900.00% | +11,011.11% | +99,900.00% | -98.41% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Medical - Pharmaceuticals: +7.8%— Q1'25: +7.7% (vs Q2'22)
-
EPS growth Medical - Pharmaceuticals: +20.2%— Q1'25: -100.0% (vs Q2'22)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%— Q1'25: -2,065.6% (vs Q2'22)
-
EBIT margin Medical - Pharmaceuticals: +6.8%— Q1'25: +84.3% (vs Q2'22)
-
ROIC Medical - Pharmaceuticals: +6.1%— Q1'25: +6.6% (vs Q2'22)
-
Share dilution Medical - Pharmaceuticals: +0.0%+4.9% Q1'25: +14.6% (vs Q2'22)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×— Q1'25: 6.28× (vs Q2'22)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Owner Earnings
Ownership Overview
Ownership breakdown not available.
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | DEL RILEY | 2.55B | 11.76% | 255.0K | — | 255.0K | — | IN | United States | 2021-04-21 | ↗ |
| 2 | Adar Bays LLC | 1.31B | 9.99% | 1.31B | — | 1.31B | — | OO | Florida | 2021-02-08 | ↗ |
| 3 | 2. | 13.47M | 9.99% | — | — | 13.47M | — | OO | Cayman Islands | 2015-05-22 | ↗ |
| 4 | Adam Baker | 6.01M | 9.90% | — | — | — | 6.01M | IN | California | 2015-02-09 | ↗ |
| 5 | Black Mountain Equities, Inc. | 6.01M | 9.90% | — | — | — | 6.01M | CO | California | 2015-02-09 | ↗ |
| 6 | Blackbridge Capital, LLC Tax Identification number: 46-1044853 | 4.90M | 9.89% | 4.90M | — | 4.90M | — | CO | Delaware | 2015-05-06 | ↗ |
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Kelvin Lindsey | Chief Executive Officer & Director | — | — |
| Kris Klassen | President | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for MDCN
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
